Hospital medicines specialist Maelor has added another distribution licence, acquiring the rights to sell Aloxi, a drug to deal with chemotherapy-induced nausea, in the UK. Aloxi has been developed by a Swiss pharma group, Helsinn Healthcare. Maelor also has the rights to an oral formulation and an extended indication for the management of post-operative nausea – both of which are in development. Maelor will be producing interim figures next Tuesday.

The shares have been a firm market of late. A current price of 13.75p compares with a recommendation level here in September last year of 6.5p. Hold.

IS Pharma	AIM	0pm	p	p
Click here for interactive charting
Other company articles:
IS Pharma			05/11/2008
Medicines group makes its mark			12/12/2007
Maelor – looking cheap again			09/11/2007
Maelor adds another drug to its distribution list			02/11/2007
Maelor upbeat			07/09/2007